The strength of our current study is the clinical findings following our previous research, firstly suggesting the homogenous phenomenon of sequence changes in graft liver CYP2C19 from the different genotypes between the donors and the recipients [9], and then further observing an association between subclinical low serum 25(OH)D in donors and fatty liver disease in recipients after LDLT [13]. The gene discussed is CYP2C19; the disease is fatty liver disease.